On 2 July 2026 the French government sent the Conseil d’État the decree setting the reimbursement rules for medical cannabis, the last outstanding step before France turns its health experiment into a regulated market. The text arrived with sign-off from the Ministry of Economy and awaits legal review after the summer recess, with publication expected at the start of the next parliamentary session. The first prescriptions under the permanent framework will not arrive before 2027.
What this decree actually decides
This is not the text that legalises medical cannabis in France: that was settled some time ago. The missing piece was the economics. The decree sets the terms of public funding and the criteria the Haute Autorité de Santé (HAS) will apply in autumn 2026 when it rules on whether these medicines deliver enough clinical benefit and at what price they are covered.
That order matters for any company looking at France. No reimbursement rules, no HAS opinion; no opinion, no price; no price, no funded prescription. Every link that slips drags the next one with it, and publication depends on a parliamentary calendar that rarely runs to schedule.
A programme that has been emptying out
The pilot began in March 2021 under ANSM supervision and reached roughly 3,000 patients. Fewer than 700 remain today: no new participants have been admitted since 2024, precisely while the permanent framework is pending. Those still enrolled keep their treatment, but the programme has been shrinking for two years for want of an entry door.
The contrast with the potential is what explains the sector’s interest. Estimates cited by the French authorities put more than 400,000 patients as potentially eligible across the five planned indications: refractory neuropathic pain, severe resistant epilepsy, spasticity linked to multiple sclerosis, side effects in oncology and palliative care. Between 700 and 400,000 lies a jump in scale that no European supply chain can absorb overnight.
What it means for producers and distributors
France joins the list of markets that open under strict conditions and with short entry windows. Some practical implications:
- EU-GMP is the filter again. As in Germany, access runs through certified pharmaceutical product. Anyone without certification already under way will arrive late to 2027.
- Demand will be neither immediate nor linear. It depends on the HAS opinion and on how fast specialist prescribers take up the indication. Planning volume against the 400,000 figure is a cash-flow mistake.
- The public payer sets the price. A reimbursed market compresses margins compared with the German or British private model. It changes the per-kilo profitability calculation.
- There is a window for advance agreements. Distribution, packaging and pharmaceutical logistics on French soil get negotiated before the market exists, not after.
France on the European board
The French move fits what we have been watching all year. Germany broke its import record with 67.5 tonnes in a single quarter and already works as the continent’s logistics hub. Spain passed its royal decree and registered the first preparations, but still has no registered manufacturer to make dispensing possible. France has the largest potential demand of the three and is the last one left to switch on.
For Spanish companies the question cuts both ways: a large neighbouring market opening up and, at the same time, confirmation that Europe’s bottleneck is no longer regulatory but industrial. Certification, production capacity and distribution agreements are what decide who invoices when the barrier lifts.
This is exactly what Spannabis B2B Bilbao 2027 is about, on 11 March at the BEC VIP Hall: access to regulated markets, certification requirements and supply agreements between producers, laboratories and distribution. If France starts prescribing that year, the useful conversations will have happened beforehand. Check the tickets or book your B2B table to close meetings with a fixed agenda.
Sources: Newsweed and Addict’Aide.